

K Gemzell-Danielsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/725443/publications.pdf>

Version: 2024-02-01

218
papers

6,684
citations

61857

43
h-index

95083

68
g-index

227
all docs

227
docs citations

227
times ranked

4803
citing authors

#	ARTICLE	IF	CITATIONS
1	Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 99, S160-7.	1.0	258
2	Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. <i>Human Reproduction Update</i> , 2011, 17, 121-137.	5.2	223
3	Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. <i>Npj Digital Medicine</i> , 2019, 2, 83.	5.7	209
4	Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. <i>Scientific Reports</i> , 2017, 7, 10077.	1.6	182
5	A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. <i>Fertility and Sterility</i> , 2012, 97, 616-622.e3.	0.5	165
6	Drivers of maternity care in high-income countries: can health systems support woman-centred care?. <i>Lancet, The</i> , 2016, 388, 2282-2295.	6.3	156
7	Telemedicine for medical abortion: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 1094-1102.	1.1	155
8	Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. <i>Human Reproduction</i> , 1993, 8, 870-873.	0.4	149
9	Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 1171-1178.	1.1	132
10	Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems. <i>Obstetrics and Gynecology</i> , 2013, 122, 1205-1213.	1.2	125
11	Expression of cyclo-oxygenase in human endometrium during the implantation period. <i>Molecular Human Reproduction</i> , 1999, 5, 961-965.	1.3	111
12	Emergency contraception "mechanisms of action. <i>Contraception</i> , 2013, 87, 300-308.	0.8	111
13	Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle"A double-blind, placebo-controlled randomized trial. <i>Psychoneuroendocrinology</i> , 2017, 76, 135-143.	1.3	103
14	Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 109, 190-195.	0.5	101
15	Health care providers' perceptions of and attitudes towards induced abortions in sub-Saharan Africa and Southeast Asia: a systematic literature review of qualitative and quantitative data. <i>BMC Public Health</i> , 2015, 15, 139.	1.2	97
16	Effect of low weekly doses of mifepristone on ovarian function and endometrial development. <i>Human Reproduction</i> , 1996, 11, 256-264.	0.4	86
17	Contraceptive use in the Nordic countries. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 19-28.	1.3	80
18	Second Trimester Medical Abortion with Mifepristone" Misoprostol and Misoprostol Alone: A Review of Methods and Management. <i>Reproductive Health Matters</i> , 2008, 16, 162-172.	1.3	79

#	ARTICLE	IF	CITATIONS
19	Acceptability of home-use of misoprostol in medical abortion. <i>Contraception</i> , 2004, 70, 387-392.	0.8	75
20	Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. <i>Fertility and Sterility</i> , 2014, 101, 1656-1662.e4.	0.5	74
21	WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.. II: Side effects and women's perceptions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 715-725.	1.1	73
22	The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. <i>Human Reproduction</i> , 2005, 20, 3072-3077.	0.4	67
23	Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. <i>Lancet, The</i> , 2015, 385, 698-704.	6.3	66
24	Perfect-use and typical-use Pearl Index of a contraceptive mobile app. <i>Contraception</i> , 2017, 96, 420-425.	0.8	66
25	Mechanism of action of emergency contraception. <i>Contraception</i> , 2010, 82, 404-409.	0.8	63
26	Early versus Delayed Insertion of Intrauterine Contraception after Medical Abortion – A Randomized Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e48948.	1.1	63
27	Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. <i>Human Reproduction</i> , 2015, 30, 800-811.	0.4	63
28	Fertility awareness-based mobile application for contraception. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 234-241.	0.6	63
29	A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding. <i>Advances in Therapy</i> , 2021, 38, 201-225.	1.3	61
30	Provision of medical abortion using telemedicine in Brazil. <i>Contraception</i> , 2014, 89, 129-133.	0.8	60
31	Use of Contraception and Attitudes towards Contraceptive Use in Swedish Women - A Nationwide Survey. <i>PLoS ONE</i> , 2015, 10, e0125990.	1.1	60
32	The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. <i>Human Reproduction</i> , 2008, 23, 2072-2079.	0.4	59
33	Emergency Contraception. <i>Gynecological Endocrinology</i> , 2013, 29, 1-14.	0.7	57
34	How the coronavirus disease 2019 pandemic is impacting sexual and reproductive health and rights and response: Results from a global survey of providers, researchers, and policy-makers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 571-578.	1.3	57
35	Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 226-231.	1.3	55
36	The CHOICE study: Effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012, 17, 65-78.	0.6	54

#	ARTICLE	IF	CITATIONS
37	Barriers and facilitators in the provision of post-abortion care at district level in central Uganda – a qualitative study focusing on task sharing between physicians and midwives. BMC Health Services Research, 2014, 14, 28.	0.9	52
38	The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 510-517.	1.1	50
39	Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days. Human Reproduction, 2010, 25, 1153-1157.	0.4	49
40	Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 210, 22-28.	0.5	49
41	The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. PLoS ONE, 2015, 10, e0135309.	1.1	49
42	Endocrinology: The effect of antiprogesterin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F _{2α} concentrations. Human Reproduction, 1994, 9, 1626-1630.	0.4	47
43	Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas, 2016, 91, 93-100.	1.0	43
44	A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertility and Sterility, 2016, 106, 151-157.e5.	0.5	43
45	Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. European Journal of Contraception and Reproductive Health Care, 2018, 23, 45-51.	0.6	43
46	Misoprostol to treat missed abortion in the first trimester. International Journal of Gynecology and Obstetrics, 2007, 99, S182-5.	1.0	42
47	Recent Advances in Understanding Endometrial Receptivity: Molecular Basis and Clinical Applications. American Journal of Reproductive Immunology, 2014, 72, 148-157.	1.2	42
48	The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. European Journal of Epidemiology, 2019, 34, 499-507.	2.5	42
49	Experiences, Feelings and Thoughts of Women Undergoing Second Trimester Medical Termination of Pregnancy. PLoS ONE, 2014, 9, e115957.	1.1	40
50	DNA methylation of HOXA10 in eutopic and ectopic endometrium. Human Reproduction, 2014, 29, 1906-1911.	0.4	40
51	A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. Contraception, 2016, 93, 507-512.	0.8	40
52	Emergency contraception: potential role of ulipristal acetate. International Journal of Women's Health, 2010, 2, 53.	1.1	39
53	Management of pain associated with the insertion of intrauterine contraceptives. Human Reproduction Update, 2013, 19, 419-427.	5.2	39
54	Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion. Contraception, 2017, 95, 437-441.	0.8	39

#	ARTICLE	IF	CITATIONS
55	Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling – results of an international survey in 10 countries. <i>Contraception</i> , 2012, 86, 631-638.	0.8	36
56	The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. <i>Human Reproduction</i> , 2015, 30, 1566-1572.	0.4	36
57	Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion – a randomized controlled equivalence trial. <i>Human Reproduction</i> , 2016, 31, 2484-2490.	0.4	35
58	Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS) – a multicentre prospective study. <i>Human Reproduction</i> , 2010, 25, 354-359.	0.4	34
59	Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial. <i>Lancet, The</i> , 2015, 385, 2392-2398.	6.3	34
60	Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. <i>The Lancet Global Health</i> , 2015, 3, e537-e545.	2.9	34
61	Mechanisms of action of oral emergency contraception. <i>Gynecological Endocrinology</i> , 2014, 30, 685-687.	0.7	33
62	Yes we can! Successful examples of disallowing “conscientious objection” in reproductive health care. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 201-206.	0.6	33
63	Human rights versus societal norms: a mixed methods study among healthcare providers on social stigma related to adolescent abortion and contraceptive use in Kisumu, Kenya. <i>BMJ Global Health</i> , 2018, 3, e000608.	2.0	33
64	Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1341-1350.	1.3	33
65	Caring for women undergoing second-trimester medical termination of pregnancy. <i>Contraception</i> , 2014, 89, 460-465.	0.8	32
66	Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile. <i>Stem Cell Research and Therapy</i> , 2020, 11, 15.	2.4	32
67	Comprehensive counseling about combined hormonal contraceptives changes the choice of contraceptive methods: results of the CHOICE program in Sweden. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 869-877.	1.3	31
68	Trends in use and attitudes towards contraception in Sweden: results of a nationwide survey. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 154-160.	0.6	31
69	Contraception following abortion and the treatment of incomplete abortion. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 126, S52-5.	1.0	30
70	Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. <i>Contraception</i> , 2019, 99, 323-328.	0.8	30
71	Safety and acceptability of medical abortion through telemedicine after 9 weeks of gestation: a population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 609-618.	1.1	30
72	Stromal Heterogeneity in the Human Proliferative Endometrium – A Single-Cell RNA Sequencing Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 448.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Estetrolâ€Drosiprenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 63-71.	1.1	30
74	Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception, 2006, 74, 31-35.	0.8	29
75	Pain during medical abortion, the impact of the regimen: A neglected issue? A review. European Journal of Contraception and Reproductive Health Care, 2014, 19, 404-419.	0.6	29
76	Effects of low doses of mifepristone on human embryo implantation process in a three-dimensional human endometrial in vitro co-culture system. Contraception, 2016, 94, 143-151.	0.8	28
77	Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemporary Clinical Trials, 2017, 55, 56-62.	0.8	28
78	Persistent organic pollutants and the size of ovarian reserve in reproductive-aged women. Environment International, 2021, 155, 106589.	4.8	28
79	Contraceptive use of antiprogestin. European Journal of Contraception and Reproductive Health Care, 1999, 4, 103-107.	0.6	27
80	Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion. Contraception, 2012, 85, 394-397.	0.8	27
81	Mode of Action of RU 486. Annals of Medicine, 1993, 25, 61-64.	1.5	26
82	Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Human Reproduction, 2014, 29, 1182-1188.	0.4	26
83	Post-abortion care with misoprostol â€œ equally effective, safe and accepted when administered by midwives compared to physicians: a randomised controlled equivalence trial in a low-resource setting in Kenya. BMJ Open, 2017, 7, e016157.	0.8	26
84	Instability of Misoprostol Tablets Stored Outside the Blister: A Potential Serious Concern for Clinical Outcome in Medical Abortion. PLoS ONE, 2014, 9, e112401.	1.1	25
85	Efficacy and safety of very early medical termination of pregnancy: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1993-1999.	1.1	25
86	Vilaprisan in women with uterine fibroids: theÂrandomized phase 2b ASTEROID 1 study. Fertility and Sterility, 2019, 111, 240-248.	0.5	25
87	Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis. PLoS ONE, 2016, 11, e0158645.	1.1	25
88	Women's Acceptability of Misoprostol Treatment for Incomplete Abortion by Midwives and Physicians - Secondary Outcome Analysis from a Randomized Controlled Equivalence Trial at District Level in Uganda. PLoS ONE, 2016, 11, e0149172.	1.1	23
89	Uterine fluid microRNAs are dysregulated in women with recurrent implantation failure. Human Reproduction, 2022, 37, 734-746.	0.4	23
90	GSTM1 Gene Expression Correlates to Leiomyoma Volume Regression in Response to Mifepristone Treatment. PLoS ONE, 2013, 8, e80114.	1.1	22

#	ARTICLE	IF	CITATIONS
91	Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT. <i>Human Reproduction</i> , 2015, 30, 1314-1322.	0.4	21
92	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	5.8	21
93	Time to act“ comprehensive abortion care in east Africa. <i>The Lancet Global Health</i> , 2016, 4, e601-e602.	2.9	20
94	Compartmentalized gene expression profiling of receptive endometrium reveals progesterone regulated ENPP3 is differentially expressed and secreted in glycosylated form. <i>Scientific Reports</i> , 2016, 6, 33811.	1.6	20
95	Oestrogen-free oral contraception with a 4“mg drospirenone-only pill: new data and a review of the literature. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020, 25, 221-227.	0.6	20
96	Acceptability of Home-Assessment Post Medical Abortion and Medical Abortion in a Low-Resource Setting in Rajasthan, India. Secondary Outcome Analysis of a Non-Inferiority Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0133354.	1.1	19
97	Prevention of unintended pregnancy and use of contraception“important factors for preconception care. <i>Uppsala Journal of Medical Sciences</i> , 2016, 121, 252-255.	0.4	19
98	Abortion and contraceptive use stigma: a cross-sectional study of attitudes and beliefs in secondary school students in western Kenya. <i>Sexual and Reproductive Health Matters</i> , 2019, 27, 20-31.	0.7	19
99	Cellular therapies for the endometrium: An update. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 672-677.	1.3	19
100	Online access to abortion medications: a review of utilization and clinical outcomes. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 63, 74-86.	1.4	19
101	Recent developments in the clinical use of the levonorgestrel“releasing intrauterine system. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 1177-1188.	1.3	18
102	Impact of bodyweight/body mass index on the effectiveness of emergency contraception with levonorgestrel: a pooled-analysis of three randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2015, 31, 2241-2248.	0.9	18
103	Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. <i>Climacteric</i> , 2017, 20, 285-289.	1.1	18
104	Abortion-related near-miss morbidity and mortality in 43 health facilities with differences in readiness to provide abortion care in Uganda. <i>BMJ Global Health</i> , 2021, 6, e003274.	2.0	18
105	Increasing uptake of long“acting reversible contraception with structured contraceptive counselling: cluster randomised controlled trial (the LOWE trial). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1546-1554.	1.1	18
106	Experiences of women living in Hungary seeking a medical abortion online. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 360-362.	0.6	17
107	Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone. <i>Reproductive Sciences</i> , 2018, 25, 320-328.	1.1	17
108	Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study. <i>European Journal of Epidemiology</i> , 2019, 34, 1093-1101.	2.5	17

#	ARTICLE	IF	CITATIONS
109	Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: An updated review. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1500-1513.	1.3	17
110	There is no association between combined oral hormonal contraceptives and depression: a Swedish register-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 917-925.	1.1	17
111	Misoprostol: first-line therapy for incomplete miscarriage in the developing world. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 1337-1339.	1.1	16
112	Medical students' attitudes and perceptions on abortion: a cross-sectional survey among medical interns in Maharashtra, India. <i>Contraception</i> , 2014, 90, 42-46.	0.8	16
113	Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 173-181.	1.3	16
114	Syndecan-1 modulates the invasive potential of endometrioma via TGF- β 2 signalling in a subgroup of women with endometriosis. <i>Human Reproduction</i> , 2020, 35, 2280-2293.	0.4	16
115	Sexual and reproductive health and rights of refugee and migrant women: gynecologists' and obstetricians' responsibilities. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 113-119.	1.0	16
116	Single-cell RNA sequencing of cultured human endometrial CD140b+CD146+ perivascular cells highlights the importance of in vivo microenvironment. <i>Stem Cell Research and Therapy</i> , 2021, 12, 306.	2.4	16
117	Is self-assessment of medical abortion using a low-sensitivity pregnancy test combined with a checklist and phone text messages feasible in South African primary healthcare settings? A randomized trial. <i>PLoS ONE</i> , 2017, 12, e0179600.	1.1	16
118	Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control – a randomized controlled trial. <i>Human Reproduction</i> , 2018, 33, 2002-2009.	0.4	15
119	Aberrant expression of genes associated with stemness and cancer in endometria and endometrioma in a subset of women with endometriosis. <i>Human Reproduction</i> , 2018, 33, 1924-1938.	0.4	15
120	Contraception after pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1378-1385.	1.3	15
121	Induction of labor after one previous Cesarean section in women with an unfavorable cervix: A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0200024.	1.1	14
122	Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 7-14.	0.5	14
123	Risk factors for poor neonatal outcome in pregnancies with decreased fetal movements. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1014-1021.	1.3	14
124	Thirty years of mirena: A story of innovation and change in women's healthcare. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 614-618.	1.3	14
125	Effectiveness, safety, and acceptability of first-trimester medical termination of pregnancy performed by non-doctor providers: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1928-1940.	1.1	13
126	Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero. <i>RMD Open</i> , 2020, 6, e000989.	1.8	13

#	ARTICLE	IF	CITATIONS
127	High birth rates despite easy access to contraception and abortion: a cross-sectional study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 1414-1422.	1.3	12
128	Ovarian stimulation and risk of breast cancer in Swedish women. <i>Fertility and Sterility</i> , 2017, 108, 137-144.	0.5	12
129	Labor Induction with Orally Administrated Misoprostol: A Retrospective Cohort Study. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	12
130	Contraceptive use among migrant, second-generation migrant and non-migrant women seeking abortion care: a descriptive cross-sectional study conducted in Sweden. <i>BMJ Sexual and Reproductive Health</i> , 2019, 45, 118-126.	0.9	12
131	Advantages of determining the fertile window with the individualised Natural Cycles algorithm over calendar-based methods. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 457-463.	0.6	12
132	Information on early medical abortion for women using an audiovisual animation vs face-to-face consultation: A consortium randomized and quasi-randomized trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1611-1617.	1.3	12
133	Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0Âmg over 6 cycles in female adolescents, with a 7-cycle extension phase. <i>Contraception</i> , 2020, 101, 412-419.	0.8	12
134	Modern contraceptive use among female refugee adolescents in northern Uganda: prevalence and associated factors. <i>Reproductive Health</i> , 2020, 17, 67.	1.2	12
135	Termination of second trimester pregnancy with mifepristone and gemeprost. The clinical experience of 197 consecutive cases. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 702-6.	1.3	12
136	Post Abortion Contraception. <i>Women's Health</i> , 2015, 11, 779-784.	0.7	11
137	Ecological study on the use of hormonal contraception, abortions and births among teenagers in the Nordic countries. <i>BMJ Open</i> , 2018, 8, e022473.	0.8	11
138	Does ulipristal acetate emergency contraception (ella®) interfere with implantation?. <i>Contraception</i> , 2019, 100, 386-390.	0.8	11
139	Effect of levonorgestrel emergency contraception on implantation and fertility: A review. <i>Contraception</i> , 2022, 109, 8-18.	0.8	11
140	Medical Abortion in Early Pregnancy. , 0, , 111-134.		10
141	Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. <i>Human Reproduction</i> , 2010, 25, 1423-1427.	0.4	10
142	Paracervical block as pain treatment during second-trimester medical termination of pregnancy: an RCT with bupivacaine versus sodium chloride. <i>Human Reproduction</i> , 2016, 31, 67-74.	0.4	10
143	Pain management for up to 9 weeks medical abortion â€“ An international survey among abortion providers. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 181-184.	0.5	10
144	Trial protocol: a parallel group, individually randomized clinical trial to evaluate the effect of a mobile phone application to improve sexual health among youth in Stockholm County. <i>BMC Public Health</i> , 2018, 18, 216.	1.2	10

#	ARTICLE	IF	CITATIONS
145	Vaginal bromocriptine for treatment of adenomyosis: Impact on magnetic resonance imaging and transvaginal ultrasound. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 254, 38-43.	0.5	10
146	Towards individualised contraceptive counselling: clinical and reproductive factors associated with self-reported hormonal contraceptive-induced adverse mood symptoms. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, e1.1-e8.	0.9	10
147	Telemedicine as an alternative way to access abortion in Italy and characteristics of requests during the COVID-19 pandemic. <i>BMJ Sexual and Reproductive Health</i> , 2022, 48, 252-258.	0.9	10
148	Effect of antiprogesterin, hCG and a prostaglandin analogue on human uterine contractility. <i>Contraception</i> , 1993, 47, 295-301.	0.8	9
149	Termination of second trimester pregnancy with mifepristone and gemeprost. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 702-706.	1.3	9
150	Intrauterine contraception: attitudes, practice, and knowledge among Swedish health care providers. <i>Contraception</i> , 2014, 89, 407-412.	0.8	9
151	Simplified follow-up after medical abortion using a low-sensitivity urinary pregnancy test and a pictorial instruction sheet in Rajasthan, India – study protocol and intervention adaptation of a randomised control trial. <i>BMC Women's Health</i> , 2014, 14, 98.	0.8	9
152	Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 220-226.	0.6	9
153	Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. <i>Contraception</i> , 2018, 98, 317-322.	0.8	9
154	Slow-release vaginal insert of misoprostol versus orally administered solution of misoprostol for the induction of labour in primiparous term pregnant women: a randomised controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 1148-1155.	1.1	9
155	How task-sharing in abortion care became the norm in Sweden: A case study of historic and current determinants and events. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 34-42.	1.0	9
156	Contraceptive Effectiveness of an FDA-Cleared Birth Control App: Results from the Natural Cycles U.S. Cohort. <i>Journal of Women's Health</i> , 2021, 30, 782-788.	1.5	9
157	Resveratrol inhibits steroidogenesis in human fetal adrenocortical cells at the end of first trimester. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600522.	1.5	8
158	Cross-disorder analysis of endometriosis and its comorbid diseases reveals shared genes and molecular pathways and proposes putative biomarkers of endometriosis. <i>Reproductive BioMedicine Online</i> , 2020, 40, 305-318.	1.1	8
159	The MOSEXY trial: mobile phone intervention for sexual health in youth – a pragmatic randomised controlled trial to evaluate the effect of a smartphone application on sexual health in youth in Stockholm, Sweden. <i>Sexually Transmitted Infections</i> , 2021, 97, 141-146.	0.8	8
160	Natural Cycles app: contraceptive outcomes and demographic analysis of UK users. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, 26, 105-110.	0.6	8
161	The global pandemic and changes in women's reproductive health: an observational study. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, 27, 102-106.	0.6	8
162	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. <i>Genome Biology</i> , 2022, 23, 52.	3.8	8

#	ARTICLE	IF	CITATIONS
163	Can India transition from informal abortion provision to safe and formal services?. <i>The Lancet Global Health</i> , 2016, 4, e357-e358.	2.9	7
164	Estimating abortion safety: advancements and challenges. <i>Lancet, The</i> , 2017, 390, 2333-2334.	6.3	7
165	Repeat testing for chlamydia trachomatis, a "safe approach" to unsafe sex? a qualitative exploration among youth in Stockholm. <i>BMC Health Services Research</i> , 2017, 17, 730.	0.9	7
166	Contraceptive experience and perception, a survey among Ukrainian women. <i>BMC Women's Health</i> , 2018, 18, 159.	0.8	7
167	10-year evaluation of the use of medical abortion through telemedicine: a retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, , .	1.1	7
168	Standardizing abortion research outcomes (STAR): Results from an international consensus development study. <i>Contraception</i> , 2021, 104, 484-491.	0.8	7
169	Time to Pregnancy for Women Using a Fertility Awareness Based Mobile Application to Plan a Pregnancy. <i>Journal of Women's Health</i> , 2021, 30, 1538-1545.	1.5	7
170	Evaluation of satisfaction with a model of structured contraceptive counseling: Results from the LOWE trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 2044-2052.	1.3	7
171	Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 235-247.	0.4	6
172	Familial cancer among consecutive uterine cancer patients in Sweden. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 14.	0.6	6
173	Induction of labor in women with a uterine scar. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1-6.	0.7	6
174	Medical students are afraid to include abortion in their future practices: in-depth interviews in Maharashtra, India. <i>BMC Medical Education</i> , 2016, 16, 8.	1.0	6
175	Outcome of first trimester medical termination of pregnancy: definitions and management. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 451-457.	0.6	6
176	Effect of mifepristone on the transcriptomic signature of endometrial receptivity. <i>Human Reproduction</i> , 2018, 33, 1889-1897.	0.4	6
177	Evaluating the safety, effectiveness and acceptability of treatment of incomplete second-trimester abortion using misoprostol provided by midwives compared with physicians: study protocol for a randomized controlled equivalence trial. <i>Trials</i> , 2019, 20, 376.	0.7	6
178	Twenty years of development in fertility preservation of women and girls and the challenges that remain. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 543-544.	1.3	6
179	Management of pain associated with up-to-9-weeks medical termination of pregnancy (MToP) using mifepristone-misoprostol regimens: expert consensus based on a systematic literature review. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 591-601.	0.4	6
180	Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 194-202.	0.5	6

#	ARTICLE	IF	CITATIONS
181	Overcoming barriers to levonorgestrel-releasing intrauterine system placement: an evaluation of placement of LNG-IUS 8 using the modified Evolvererter [®] in a majority nulliparous population. <i>Contraception</i> , 2017, 96, 426-431.	0.8	6
182	Reply. Letter to the editor. Hillemanns Peter, Hepp Hermann, Letter to the Editor: K. Gemzell-Danielsson et al. Emergency contraception " mechanisms of action. <i>Contraception</i> , 2013, 88, 581-582.	0.8	5
183	Short- and long-term effect of contraceptive methods on fecundity. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 260-265.	0.6	5
184	Long-acting reversible contraception and satisfaction with structured contraceptive counselling among non-migrant, foreign-born migrant and second-generation migrant women: evidence from a cluster randomised controlled trial (the LOWE trial) in Sweden. <i>BMJ Sexual and Reproductive Health</i> , 2022, 48, 128-136.	0.9	5
185	Induced abortion and access to contraception in Sweden during the COVID-19 pandemic. <i>BMJ Sexual and Reproductive Health</i> , 2022, 48, 311-312.	0.9	5
186	UPA & LNG, but Not Good Enough. <i>Contraception</i> , 2013, 88, 585-586.	0.8	4
187	"Who Wants to Go Repeatedly to the Hospital?" Perceptions and Experiences of Simplified Medical Abortion in Rajasthan, India. <i>Global Qualitative Nursing Research</i> , 2016, 3, 233339361668307.	0.7	4
188	Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA carriers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 250-261.	1.3	4
189	Reproductive changes among women in their 40s: A cross-sectional study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 248-255.	1.3	4
190	Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial. <i>Human Reproduction</i> , 2015, 30, 1573-1579.	0.4	3
191	Fertility awareness-based mobile application. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 166-168.	0.6	3
192	The human genital tubercle is steroidogenic organ at early pregnancy. <i>Molecular and Cellular Endocrinology</i> , 2018, 477, 148-155.	1.6	3
193	Management of very early medical abortion " An international survey among providers. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 246, 169-176.	0.5	3
194	Contraceptive uptake among post-abortion care-seeking women with unplanned or planned pregnancy in western Kenya. <i>Sexual and Reproductive Healthcare</i> , 2020, 23, 100486.	0.5	3
195	More than just contraception: the impact of the levonorgestrel-releasing intrauterine system on public health over 30 years. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, 228-230.	0.9	3
196	Effect of peer counselling on acceptance of modern contraceptives among female refugee adolescents in northern Uganda: A randomised controlled trial. <i>PLoS ONE</i> , 2021, 16, e0256479.	1.1	3
197	Effects of levonorgestrel on ovarian function when used for emergency contraception. <i>Minerva Ginecologica</i> , 2006, 58, 205-7.	0.8	3
198	Abortion: legislation and statistics in Europe. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, , 1-8.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Comment on "Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives": authors' response. <i>Journal of Family Planning and Reproductive Health Care</i> , 2014, 40, 235.2-235.	0.9	2
200	The importance of considering the evidence in the MTP 2014 Amendment debate in India "unsubstantiated arguments should not impede improved access to safe abortion. <i>Global Health Action</i> , 2015, 8, 27512.	0.7	2
201	Co-creation to scale up provision of simplified high-quality comprehensive abortion care in East Central and Southern Africa. <i>Global Health Action</i> , 2018, 11, 1490106.	0.7	2
202	Response to "study of contraceptive mobile app fails to provide convincing findings". <i>Contraception</i> , 2019, 99, 195-196.	0.8	2
203	Hand-held device to remove a single-rod subdermal contraceptive implant: Results of early trials in Sweden. <i>Contraception</i> , 2020, 102, 424-427.	0.8	2
204	Detection of ectopic pregnancy and serum beta hCG levels in women undergoing very early medical abortion: a retrospective cohort study. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, , 1-7.	0.6	2
205	Germline stem cells: new insights into female infertility management. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 309-311.	0.4	1
206	Routine misoprostol before all surgical abortions. <i>Contraception</i> , 2016, 94, 575-576.	0.8	1
207	Does mode of follow-up influence contraceptive use after medical abortion in a low-resource setting? Secondary outcome analysis of a non-inferiority randomized controlled trial. <i>BMC Public Health</i> , 2016, 16, 1087.	1.2	1
208	Self-assessment of success of early medical abortion using a self-performed urine pregnancy test. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 319-321.	0.6	1
209	Exploring health care providers' experiences of and perceptions towards the use of misoprostol for management of second trimester incomplete abortion in Central Uganda. <i>PLoS ONE</i> , 2022, 17, e0268812.	1.1	1
210	New clinical data on consecutive use of the levonorgestrel-releasing intrauterine system. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 275-277.	0.4	0
211	Response to the editorial "Menopausal health: the potential for fetal-placental estrogen use". <i>Maturitas</i> , 2016, 94, 181.	1.0	0
212	When endometriosis is the barrier for fertility. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 621-622.	1.3	0
213	Clarifications concerning contraceptive mobile app Pearl Index calculations. <i>Contraception</i> , 2018, 97, 456-457.	0.8	0
214	Time to act "reaching the sexual and reproductive health goals of Agenda 2030. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 905-906.	1.3	0
215	Mechanisms of action of emergency contraception pills. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 11-12.	0.6	0
216	Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 330-335.	0.5	0

#	ARTICLE	IF	CITATIONS
217	Celebrating 100 years of <i>AOGS</i> with a focus on global health. Acta Obstetrica Et Gynecologica Scandinavica, 2021, 100, 561-563.	1.3	0
218	EffektivitÄt der VerhÄtungs-App Natural Cycles in Deutschland im Vergleich zu Australien, Schweden und Finnland. , 2018, 78, .		0